US Patent

US10272064 — Pharmaceutical formulations for subcutaneous administration of furosemide

Formulation · Assigned to ScPharmaceuticals Inc · Expires 2034-04-03 · 8y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects liquid pharmaceutical formulations of furosemide (Lasix) suitable for subcutaneous administration.

USPTO Abstract

The present teachings relate to liquid pharmaceutical formulations of furosemide, where the pharmaceutical formulations include a molar excess of tris(hydroxymethyl)aminomethane to furosemide, have a pH in the range of 7 to 8.5, and a concentration of tris(hydroxymethyl)aminomethane greater than or equal to about 50 mM. The present teachings can improve the stability of liquid pharmaceutical formulations including furosemide and the suitability of such pharmaceutical formulations for subcutaneous administration or delivery.

Drugs covered by this patent

Patent Metadata

Patent number
US10272064
Jurisdiction
US
Classification
Formulation
Expires
2034-04-03
Drug substance claim
No
Drug product claim
Yes
Assignee
ScPharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.